Future Outlook & Investigational Therapies for ADNP Syndrome

As you look toward the future, it is natural to wonder what life will look like for your child as they grow. While ADNP syndrome is a lifelong journey, our understanding of the long-term outlook is growing every day. Research confirms that individuals with ADNP syndrome live into adulthood, where they continue to learn, grow, and thrive with appropriate supportive care ^[1][2].

Adulthood and Long-Term Outlook

Because ADNP syndrome was only recently discovered (in 2014), we are still learning about the full spectrum of the condition in older individuals. However, current medical literature and case reports provide several key insights:

• Longevity: Individuals with ADNP syndrome reach adulthood ^[1]. While data on life expectancy is still being gathered, the focus of clinical care is on managing symptoms to ensure a high quality of life throughout the lifespan ^[3][2].
• Adult Manifestations: As children with ADNP reach their late teens and 20s, new physical traits may emerge. These can include truncal obesity (weight gain around the midsection), hirsutism (excessive hair growth), and continued intellectual disability or speech impairment ^[1].
• Developmental Trajectory: While developmental progress may be slow, it is not “static.” Individuals often continue to make gains in communication and social interaction well into their adult years, though most will require lifelong assistance with daily living ^[4][5].

The Research Pipeline: Investigational Therapies

The most exciting area of ADNP research involves targeted pharmacological therapies—treatments designed to address the underlying genetic cause rather than just the symptoms.

NAP (Davunetide)

The most prominent investigational drug in the ADNP pipeline is NAP (also known as davunetide) ^[6][7].

• The Mechanism: NAP is a small fragment of the ADNP protein itself. Researchers have found that it can cross the blood-brain barrier and act as a “booster” for the brain’s internal skeleton ^[6][8].
• Addressing Tauopathy: In ADNP syndrome, the “skeleton” of brain cells (microtubules) becomes unstable, leading to a microscopic build-up of a protein called tau. This process is known as tauopathy ^[9][7]. (Note: While tauopathy is a term also used in adult neurodegenerative diseases, in ADNP syndrome, researchers are focused on how this protein buildup affects early brain development and cell communication, rather than causing dementia). NAP is being studied for its ability to stabilize these microtubules and protect brain cells from damage ^[8][10].
• Status: NAP has shown significant promise in preclinical (animal) models, where it improved cognitive and behavioral symptoms ^[8][11]. It is currently positioned for further clinical development in human trials ^[6][7].

Low-Dose Ketamine Trials

Another area of active clinical research is the use of low-dose ketamine. In laboratory settings, ketamine has shown potential to increase the expression of the ADNP gene and improve certain developmental pathways ^[12][7].
Important Safety Note: The ketamine used in these trials is highly regulated, carefully dosed, and strictly monitored. Parents should never seek out commercial, off-label ketamine clinics for their child. Unmonitored use poses severe safety risks to a developing brain. Any treatment should only be pursued within the framework of an approved clinical trial.

mTOR Inhibitors

Another emerging area of research focuses on mTOR inhibitors (such as everolimus) ^[13]. These drugs, already used for other conditions, may help “rebalance” the signaling pathways in the brain that are disrupted by ADNP deficiency. Preclinical studies suggest they may improve social and cognitive behaviors, though they are not yet a standard of care for ADNP syndrome ^[13].

Building a Bridge to the Future

While these treatments are currently investigational (meaning they are still being tested for safety and efficacy), they represent a shift toward precision medicine for ADNP syndrome. The goal of this research is not to “fix” your child, but to provide them with tools that support their brain health and maximize their potential for independence ^[6][3]. In the meantime, the most powerful intervention remains the consistent, multisystem support and therapies you are already providing ^[14].